1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Insys seeks fast cash, Nasdaq listing with IPO

 
• By Mandy Jackson

Insys Therapeutics intends to raise up to $82.8 million in an initial public offering of 4 million shares priced at $16 to $18 each plus the sale of additional shares to meet overallotments; the IPO would move the Phoenix, Arizona-based company to the Nasdaq from the Over-the-Counter market to generate much needed cash from a larger pool of investors.

Insys Therapeutics intends to raise up to $82.8 million in an initial public offering of 4 million shares priced at $16 to $18 each plus the sale of additional shares to meet overallotments; the IPO would move the Phoenix, Arizona-based company to the Nasdaq from the Over-the-Counter market to generate much needed cash from a larger pool of investors.

Insys, which focuses on cancer supportive care and other products, closed at $11.99 per share on 19 April on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

More from Therapeutic Category

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.